Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Edited. Just responding in regards to the companies mentioned in the inquiry
Here's the SEC 8-K filing...
"On June 17, 2024, Elite Pharmaceuticals, Inc. (the “Company”) and Nostrum Laboratories Inc. (“Nostrum”) entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), pursuant to which Nostrum was obligated to (i) sell to the Company all of its rights in and to the approved abbreviated new drug applications (ANDAs) for generic Norco® (Hydrocodone Bitartrate and Acetaminophen tablets, USP CII), generic Percocet® (Oxycodone Hydrochloride and Acetaminophen, USP CII), and generic Dolophine® (Methadone Hydrochloride tablets), each a “Product”, and (ii) grant to the Company a royalty-free, non-exclusive perpetual license to use the manufacturing technology, proprietary information, processes, techniques, protocols, methods, know-how, and improvements necessary or used to manufacture each Product in accordance with the applicable ANDA, in exchange for $900,000 in cash (the “Transaction”). The Asset Purchase Agreement includes customary representations and warranties and various customary covenants. The closing of the Transaction occurred on June 21, 2024."
https://www.sec.gov/ix?doc=/Archives/edgar/data/1053369/000149315224024720/form8-k.htm
On the last conference call I remember Nasrat saying these product will be sold under Elite label.
Although the side effects of the drug are a rarity, study lead author Lauren Moran said doctors who prescribe these stimulants for attention-deficit/hyperactivity disorder should "maybe stay away from (higher) doses, or just make sure that you're carefully monitoring patients."
This is just a study ( sponsored by the maker of ADHD drug Ritalin??? ).
"The study found no such link for another common ADHD medication methylphenidate, which is sold under the brand name Ritalin."
FDA will make the final say....
Took a screen shot on this post for reference >>> insider trading <<<
It seems Nasrat made a good move in selling the Vigabatrin to Pyros. The FDA approved the drug for 25 companies (including Pyros) yesterday. Too much competition.
With that resulting move and trade reaction, It's obviously been gobbled up by MMs. Now watch them run this UP.
MM's GTSM and INTL are the ones holding us. Crooks!
We might be busting through the .31's before power hour comes. imo
Buy: 1,856,295 ---- Neutral: 108,200 ---- Sell: 665,045
source: ELTP trades (ihub) as of now
Almost a million traded in .30 as of now
You are welcome. Glad to be of help. Please kindly share his feedback when you get the chance. Thanks!
From previous CC:
"Since the launched of ELTP's own Marketing & Sales Infrastructure in April 2023 it has developed a new customer relationship with at least 27 companies including Cardinal Health, CVS, Walgreens, Myers, Publix, and McKesson as of 1Q Fiscal Year 2024 ended June 30, 2023."
Most likely more than 27 companies to date. imo
I hope this helps.
iHub is off. Thanks for the reinforcement! :)
I see... lol
How can it be an after hour trade when it's showing a "buy" for 100 shares occurs at 16:00:00. Yahoo is also showing .2855 close at 4:00 PM EDT. So... which closing price is right?
Dexcel no deep pocket? Sure?
Just hinted to me "Dexcel Pharma", having acquired a subsidiary, Edenbridge Pharmaceuticals couple years ago. Renting a 15,000 sq.ft. (second floor) of a commercial building somewhere in NJ. Why not acquire Elite and combine both in one location. Hmmmm....
Definitely some members have other accounts. I thought the site is new that is why I suggested posting it there. Its your call. Thanks anyways...
Thank you Lazarus Elite!
Awesome! Thank you! You should post it here too https://www.reddit.com/r/RobinHoodPennyStocks/
Thank you!
Tell your PUPPETMASTER to flash it again and see what will happen.
F@#@##l. Take a hike!
Tell your boss time is running out fast. Gotta cover that bloated short position.
It's just so annoying of such criminal act! F@##$#$$ them!!!
Now it's gone. F@@##$$% criminal!
INTL on the ask 2,000,000 shares @ -195. SPOOFING !!! Damn @#@#$$% WATCH IT!
Got it. Thanks!
Nice! Would you mind posting this at ymb too? thanks!
FWIW to Nasdaq Listed Entities.
Nasdaq (NASDAQ:NDAQ) – Nasdaq is proposing changes to expedite the delisting of penny stocks that fail to meet the closing price criterion above $1 for 30 consecutive days. If approved, the process will be faster, eliminating the appeal option after 360 days and penalizing companies that execute reverse splits to manipulate prices.
21,777,000 thank you!
Partnership in product development (ART - NDAs ) - Nasrat's 1 of 3 pronged approach...
"A few years ago, we shifted the company’s focus and we created a three-pronged approach. The three basket approach. One is the NDAs and the AR technology. Two is partnerships in order to elevate cost and bring in ideas and three is our own product."
https://www.insidermonkey.com/blog/elite-pharmaceuticals-inc-pnkeltp-q3-2024-earnings-call-transcript-1259859/4/
The thing is it's up to us, true longs, to stop this nonsense. Enough is enough. Fight!!!...fight!!!
Parties are requesting for an extension of the temporary "stay". Must be good sign? :) To note: Purdue's counsel made the filing.
"Letter from Wayne Fang, on behalf of all parties, requesting an extension of the temporary stay re21 Stipulation and Order.(FANG, WAYNE)"
Elite Pharmaceuticals (otcqb: ELTP) - market OUTPERFORM recommendation Coverage!
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation?art_rec=quote-stock_overview-zacks_news-ID02-txt-2300922
Elite Pharmaceuticals - Market OUTPERFORM Recommendation Coverage!
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation?art_rec=quote-stock_overview-zacks_news-ID02-txt-2300922
Elite Pharmaceuticals - Market OUTPERFORM Recommendation Coverage!
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation?art_rec=quote-stock_overview-zacks_news-ID02-txt-2300922
Elite Pharmaceuticals - Market OUTPERFORM Recommendation Coverage!
https://www.zacks.com/stock/news/2300922/zacks-initiates-coverage-of-elite-pharmaceuticals-with-outperform-recommendation?art_rec=quote-stock_overview-zacks_news-ID02-txt-2300922